Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bruker (BRKR)

Bruker expects Q1 2025 revenue of $795 million to $800 million, ahead of its outlook

Positive Impact 3 of 5 earnings Written later

Bruker Corporation said in an 8-K that preliminary first-quarter 2025 revenue for the period ended March 31, 2025 is expected to be $795 million to $800 million, which the company says compares favorably with its earlier outlook and consensus. The figures are unaudited, have not been reviewed by the independent auditor, and could change during quarter-end closing, so the company warns that undue reliance should not be placed on them. Final first-quarter results are scheduled for May 7, 2025.

Key points

  • Preliminary Q1 2025 revenue range: $795 million to $800 million, implying reported growth of about 10% year over year
  • Estimated non-GAAP organic revenue growth in the low-single digit percentages, with mid-single digit growth in the BSI segment and a high-teens percentage decline in the BEST segment
  • Final first-quarter 2025 results to be released before market opening on May 7, 2025, with a conference call at 8:30 a.m. Eastern Daylight Time

The filing

CompanyBruker (BRKR)
Form8-K, current report
Filed with the SECApr 11, 2025, 8:00 AM ET
Accession number0000950170-25-053032

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.